• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Brent Passer

Instructor, Department of Surgery, Harvard Medical School

Instructor, Neurosurgery, Massachusetts General Hospital

Contact Info

Brent Passer
Massachusetts General Hospital
185 Cambridge St
Boston, MA, 02114
Mailstop: CPZN-3-3800
Phone: 617-726-6798


Not Available.

DF/HCC Program Affiliation

Prostate Cancer
Translational Pharmacology and Early Therapeutic Trials

Research Abstract

The major focus of my research has been on the application of replication-competent oncolytic herpes-simplex viruses (oHSV) for the treatment of prostate cancer. Oncolytic HSV-based vectors can replicate within and kill tumor cells (oncolysis), sparing normal cells. One major drawback is its limited capacity to spread intercellularly and kill neighboring cancer cells. To improve the clinical utility of oHSV-based therapies for prostate cancer, my ongoing studies have focused on the identification of chemotherapeutic agents and/or small molecule compounds that modulate important prostate cancer cell pathways and, when paired with appropriate oHSV vectors can increase oncolytic cancer cell destruction. I have pursued this line of research using two interrelated strategies: 1) Screened several FDA-approved chemotherapeutic agents in conjunction with oHSV to identify a synergistic combination that results augmented cell death both in vitro and in vivo. 2) Undertook an unbiased high-throughput chemical library screen to identify small molecule compounds that promote augmented oHSV spread in human prostate cancer cells. The coupling of oHSV virotherapy with small molecule discovery has allowed us to uncover novel pathways of viral oncolysis in prostate cancer and moreover, has led to increased efficacy in preclinical testing.


View All Publications